ARWR Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -82.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $57.67, signalling downside risk potential of -10.82%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.47%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, which suggesting that the stock is 27.862% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 10.41x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of 28.26%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Novartis AG's return on equity of 33.87%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $57.67, signalling downside risk potential of -10.82%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 1.85%. Given that Novartis AG has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Novartis AG is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, which suggesting that the stock is 27.862% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.02% to investors and pays a quarterly dividend of $3.99 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Novartis AG quarterly revenues of $13.9B. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is lower than Novartis AG's net income of $3.9B. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 10.41x versus 4.79x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of 21.32%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Pfizer Inc.'s return on equity of 10.84%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $57.67, signalling downside risk potential of -10.82%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Pfizer Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, which suggesting that the stock is 27.862% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 10.41x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -45.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $57.67, signalling downside risk potential of -10.82%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $19.91 which suggests that it could fall by -12.76%. Given that Sarepta Therapeutics, Inc. has more downside risk than Arrowhead Pharmaceuticals, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, which suggesting that the stock is 27.862% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 10.41x versus 0.98x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.